Forteo
(Teriparatide)ApprovedPeptide
Teriparatide is used to treat osteoporosis (weak bones) by stimulating bone formation and increasing bone density, helping to reduce the risk of fractures.[2] Forteo is currently approved and in use across 22 indications[4].[1]
Forteo is one of 373 small molecule programs targeting Arthropathy. It is currently in Approved.
22
Indications
121
Total Trials
12
Active Trials
372
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 22 indications
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Forteo
AAlmaject
Approved
Rituxan
RochePreclinical
Orencia
Bristol-Myers SquibbPreclinical
Actemra
RochePreclinical
Cimzia
UCBPreclinical
Simponi
Johnson & JohnsonPreclinical
Enbrel
IImmunex
Preclinical
Remicade
OOrganon and Co
Preclinical
Arcoxia
NovartisPreclinical
Kevzara
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Osteoporosis38 trials
Show 35 more trials
Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis
Completed·—·Phase 3·NCT01611571·31 enrolled
Parathyroid Hormone (PTH) With Alendronate for Osteoporosis
Completed·—·Phase 2·NCT00005006·140 enrolled
Adherence to Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication
Completed·—··NCT02472782·851 enrolled
Replication of the VERO Osteoporosis Trial in Healthcare Claims Data
Completed·—··NCT04879420·12,757 enrolled
Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
Completed·—·Phase 2/3·NCT00697463·22 enrolled
Postmenopausal Osteoporosis8 trials
Weekly vs Daily Teriparatide Therapy in Severe Postmenopausal Osteoporosis
Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·N/A·NCT01760798·20 enrolled
Show 5 more trials
Treatment7 trials
Sequential Therapies After Osteoanabolic Treatment
Recruiting·—··NCT06164795·150 enrolled
Show 4 more trials
Postmenopausal Women6 trials
Show 3 more trials
Fracture6 trials
36 more indications
Hip Fracture3 trials
Bone3 trials
Cyclic Versus Daily Teriparatide on Bone Mass
Unknown status·—·Phase 2·NCT00668941·140 enrolled
Spinal Cord Injury3 trials
Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury
Completed·—·Phase 2·NCT01225055·60 enrolled
Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)
Completed·—·Phase 4·NCT00826228·12 enrolled
Low Bone Mineral Density2 trials
Osteogenesis Imperfecta2 trials
Thyroid2 trials
Hypocalcemia2 trials
Oral2 trials
Clinical Trial2 trials
Hypoparathyroidism2 trials
Trial2 trials
Secondary Hyperparathyroidism1 trial
Chronic Kidney Disease1 trial
Lumbar Fusion Surgery1 trial
Metabolism1 trial
Circulating Myokine Levels and Bone Metabolism
Completed·—··NCT04206618·220 enrolled
Renal Osteodystrophy1 trial
Renal Osteodystrophy: An Individual Management Approach
Completed·—·N/A·NCT02440581·141 enrolled
Fractures1 trial
Vertebral Compression Fracture1 trial
Sex1 trial
Pharmacokinetic and PHarmacodynamic Analysis and Evaluation of Teriparatide (PTH 1-34) Between Sexes
Completed·—·Phase 3·NCT04921124·30 enrolled
Arthropathy1 trial
Efficacy of Teriparatide in Diabetic Inactive Charcot Neuroarthropathy of Foot
Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2·NCT02023411·20 enrolled
Rheumatoid Arthritis1 trial
Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial
Completed·—·Phase 4·NCT01400516·26 enrolled
Osteocalcin1 trial
Efficacy and Safety1 trial
Ankle Fracture1 trial
Femur Fracture1 trial
Unspecified7 trials
The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL
Withdrawn·—·N/A·NCT00347737
Regulatory
FDA Approval Timeline[5]
Dec 23, 1987
PARATHAR
NDA NDA019498
Jun 25, 2008
FORTEO
NDA NDA021318
Oct 4, 2019
BONSITY
NDA NDA211939
Jun 4, 2024
TERIPARATIDE
NDA NDA218771
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Forteo drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Teriparatide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]